CGM shows semaglutide stabilizes glucose in Ramadan fasting

Key Takeaways

• Adding semaglutide or tirzepatide to insulin improved time‑in‑range during Ramadan fasting.
• Adjunct therapy halved post‑iftar glucose excursions compared to insulin alone.
• The combination held glucose metrics steady without increasing hypoglycemia.
• Patients tolerated the add‑on therapy well throughout the fast.

What did the CGM study find?

Continuous glucose monitoring tracked glycemic control during Ramadan fasting in people using semaglutide or tirzepatide with insulin. Participants with type 2 diabetes on basal‑bolus insulin who added semaglutide or tirzepatide maintained a much higher time in range—74.4 % versus 36.8 % for insulin alone (p = 0.007). The glucose management indicator also improved: 6.9 % versus 8.3 % (p = 0.004). Post‑iftar area under the curve for glucose dropped by about 61 % with add‑on therapy (102,014 vs 260,578 mg/dL·min over 4 h), producing smoother glycemia during the non‑fasting hours. The study tracked matched cohorts during Ramadan in 2025 and reported no increase in hypoglycemia or treatment discontinuations ScienceDirect.

Why does post‑iftar hyperglycemia matter during Ramadan?

Ramadan dysglycemia in insulin‑treated individuals stems largely from post‑iftar surges in glucose. CGM profiles show a sharp rise after the evening meal that drives most control issues. Those on basal‑bolus insulin alone saw marked deterioration in glycemia during non‑fasting hours. The add‑on therapy blunted that surge and steadied glucose despite the meal timing shift ScienceDirect.

Was adjunct semaglutide or tirzepatide safe during fast?

The study reported no treatment discontinuations during Ramadan, and hypoglycemia did not increase. Participants tolerated semaglutide or tirzepatide while fasting. CGM data showed no rise in time below range, and coefficient of variation stayed stable, indicating no new safety concerns when adding these agents to insulin during Ramadan ScienceDirect.

FAQ

What does the CGM study show about semaglutide during Ramadan fasting?

Adding semaglutide to insulin improves time‑in‑range and reduces post‑iftar hyperglycemia during Ramadan fasting in insulin‑treated type 2 diabetes patients.

Does tirzepatide help similarly to semaglutide in this CGM study?

Yes. The study included both semaglutide and the dual GLP‑1/GIP agonist tirzepatide as add‑on therapy, and both stabilized glycemic control during Ramadan fasting.

Did adding semaglutide or tirzepatide increase risk of hypoglycemia?

No. CGM metrics showed no increase in time below range or glucose variability, and the therapies were well tolerated with no discontinuations during Ramadan.

How much did time in range improve with adjunct therapy?

Time in range improved to 74.4 % in the semaglutide or tirzepatide group compared with 36.8 % in the insulin‑only group during Ramadan fasting.

Why is post‑iftar glucose control critical during Ramadan?

Post‑iftar glucose surges drive most of the dysglycemia in insulin‑treated patients during Ramadan. Controlling that meal‑related spike is key to maintaining glycemic stability.

Not medical advice. GLP‑1 medications are prescription drugs and fasting is not right for everyone. Talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.